Biogen Inc and partner Eisai Co Ltd said on Friday they would abandon two late-stage trials testing experimental Alzheimer’s treatment elenbecestat, months after scrapping trials of another drug for the memory-robbing disease. The companies said the decision was based on the results of a review conducted by a data safety monitoring board, which recommended discontinuing the trials as the treatment’s benefits did not outweigh its risks. The companies in March ended two late-stage trials of another experimental Alzheimer’s disease drug, aducanumab.

source https://finance.yahoo.com/news/1-biogen-scraps-two-stage-124442757.html?.tsrc=rss